enGene Holdings Inc

enGene Holdings Inc through its subsidiary enGene Inc operates as a clinicalstage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs Its lead product candidate is EG70 detalimogene voraplasmid which is a nonviral immunotherapy to treat nonmuscle invasive bladder cancer patients with carcinomainsitu Cis who are unresponsive to treatment with Bacillus CalmetteGuerin The company was founded in 2023 and is based in SaintLaurent Canada